5 Stocks Pushing The Health Services Industry Lower

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 31 points (0.2%) at 15,006 as of Tuesday, July 2, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,611 issues advancing vs. 1,325 declining with 103 unchanged.

The Health Services industry currently sits down 0.4% versus the S&P 500, which is up 0.4%. A company within the industry that increased today was Grifols ( GRFS), up 0.9%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is down $3.30 (-9.3%) to $32.20 on heavy volume. Thus far, 1.2 million shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 180,700 shares. The stock has ranged in price between $32.09-$32.72 after having opened the day at $32.41 as compared to the previous trading day's close of $35.50.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $21.4 billion and is part of the health care sector. The company has a P/E ratio of 18.3, above the S&P 500 P/E ratio of 17.7. Shares are up 3.5% year to date as of the close of trading on Monday. Currently there are 4 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, DaVita HealthCare Partners ( DVA) is down $6.15 (-5.1%) to $115.00 on heavy volume. Thus far, 3.3 million shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 778,000 shares. The stock has ranged in price between $113.83-$117.08 after having opened the day at $115.00 as compared to the previous trading day's close of $121.15.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $12.8 billion and is part of the health care sector. The company has a P/E ratio of 29.3, above the S&P 500 P/E ratio of 17.7. Shares are up 9.3% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Becton Dickinson ( BDX) is down $1.39 (-1.4%) to $97.86 on average volume. Thus far, 398,990 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $97.84-$99.15 after having opened the day at $99.13 as compared to the previous trading day's close of $99.25.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company's BD Medical segment produces medical devices that are used in various healthcare settings. Becton Dickinson has a market cap of $19.2 billion and is part of the health care sector. The company has a P/E ratio of 17.7, equal to the S&P 500 P/E ratio of 17.7. Shares are up 26.4% year to date as of the close of trading on Monday. Currently there are 4 analysts that rate Becton Dickinson a buy, 5 analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Becton Dickinson Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Humana ( HUM) is down $1.11 (-1.3%) to $84.08 on light volume. Thus far, 379,542 shares of Humana exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $83.81-$85.22 after having opened the day at $85.00 as compared to the previous trading day's close of $85.19.

Humana Inc., a health care company, offers insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in three segments: Retail, Employer Group, and Health and Well-Being Services. Humana has a market cap of $13.3 billion and is part of the health care sector. The company has a P/E ratio of 9.5, below the S&P 500 P/E ratio of 17.7. Shares are up 24.1% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Humana a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Humana Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is down $1.03 (-1.2%) to $85.32 on light volume. Thus far, 785,304 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $85.00-$86.33 after having opened the day at $86.08 as compared to the previous trading day's close of $86.35.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $30.4 billion and is part of the health care sector. The company has a P/E ratio of 23.6, above the S&P 500 P/E ratio of 17.7. Shares are up 35.4% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Thermo Fisher Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug